The Onco'Zine Brief
The Onco'Zine Brief is an interview and discussion program presented by Peter Hofland and covers a broad range of topics and timely news updates with information from all oncology disciplines and sub-specialties from around the world. The Onco'Zine Brief is a sponsor-supported, program for healthcare professionals involved in the management and care of cancer patients as well as cancer patients and their family and friends. If you like to join us as a sponsor or advertisers, download our media kit (https://adc.expert/oncozine_media_kit). If you are living in the US, sign up for our newsletter by texting the words CANCER to 66866.
Episodes
August 14, 2023 • 41 mins
In a new episode of The Onco'Zine Brief, Peter Hofland talks with David M. Cognetti, MD, a Professor and Chair in the Department Head and Neck Surgery at Thomas Jefferson University Hospital in Philadelphia.
Hofland and Cognetti talk about head and neck cancer and a novel treatment approach called Photoimmunotherapy.
Head and Neck Cancer
According to the American Cancer Society, Head and neck cancer accounts for about 4% of all cance...
Hofland and Cognetti talk about head and neck cancer and a novel treatment approach called Photoimmunotherapy.
Head and Neck Cancer
According to the American Cancer Society, Head and neck cancer accounts for about 4% of all cance...
Mark as Played
April 16, 2023 • 44 mins
In this episode of The Onco'Zine Brief, Peter Hofland talks with two experts about their research and the impact the outcomes from these studies may have on the treatment of patients diagnosed with cancer.
First, Hofland talks with Christopher Heery, MD.
Dr Heery is a board-certified medical oncologist with primary expertise in the translational and clinical development of immunotherapies, including, but not limited to PD-L1 inhibit...
First, Hofland talks with Christopher Heery, MD.
Dr Heery is a board-certified medical oncologist with primary expertise in the translational and clinical development of immunotherapies, including, but not limited to PD-L1 inhibit...
Mark as Played
March 14, 2023 • 44 mins
Antibody-drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. However, unlike chemotherapy, ADCs are intended to directly target and kill tumor cells while, at the same time sparing normal, healthy cells.
Antibody-drug conjugates consist of three parts:
Antibody-drug conjugates consist of three parts:
- an antibody specific to the target associated antigen,
- a payload (sometimes calles a warhead) designed to kill target...
Mark as Played
February 17, 2023 • 41 mins
In December 2022 the annual meeting of the American Society of Hematology took place in the vibrant city of New Orleans and brought together tens of thousands of participants from across the world to present and discuss the results of studies that ranged from initial hypothesis to practice-changing results.
In this episode of The Onco’Zine Brief Peter Hofland talks to two people about their research and the impact the outcomes from ...
In this episode of The Onco’Zine Brief Peter Hofland talks to two people about their research and the impact the outcomes from ...
Mark as Played
January 17, 2023 • 41 mins
In the 100th episode of the Onco’Zine Brief, Peter Hofland, Ph.D. talks with Stephen Spellman, Vice President of Research and Senior Scientific Director of the Center for International Blood and Marrow Transplant Research at the National Marrow Donor Program/Be the Match.
In the program today Hofland and Spellman talk about bone-marrow transplants.
The likelihood of finding a fully matched unrelated donor for a patient who needs a b...
In the program today Hofland and Spellman talk about bone-marrow transplants.
The likelihood of finding a fully matched unrelated donor for a patient who needs a b...
Mark as Played
November 29, 2022 • 48 mins
In this edition of The Onco'Zine Brief, Peter Hofland, Ph.D, talks with Susanna F. Greer, Ph.D. the Chief Scientific Officer of the V Foundation. In her role, Dr. Greer is a visionary ambassador of the V Foundation, who works with the foundation’s Scientific Advisory Committee to steer funding to the most promising research opportunities.
An accomplished strategist, she develops and articulates priorities to enhance the V Foundation...
An accomplished strategist, she develops and articulates priorities to enhance the V Foundation...
Mark as Played
October 27, 2022 • 39 mins
Despite availability of endocrine therapies for advanced or metastatic breast cancer, there remains a critical unmet need for more effective and convenient treatment options that improve both the patient experience and health outcomes.
In today’s episode of The Onco’Zine Brief, Peter Hofland, Ph.D. talks with Sean P. Bohen, MD, Ph.D., the president and Chief Executive Officer of Olema Therapeutics.
Olema Terapeutics is developing ne...
In today’s episode of The Onco’Zine Brief, Peter Hofland, Ph.D. talks with Sean P. Bohen, MD, Ph.D., the president and Chief Executive Officer of Olema Therapeutics.
Olema Terapeutics is developing ne...
Mark as Played
October 1, 2022 • 49 mins
The annual congress of the European Society for Medical oncology or ESMO, is one of the most influential oncology meetings for clinicians, researchers, patient advocates, and healthcare industry representatives from all over the world. This year the annual Congress was held September 9 - 13, 2022 in the Paris Expo Porte de Versailles in Paris, France.
In this episode of the Onco’Zine Brief, Peter Hofland, Ph.D., talks with:
- Eric Vi...
In this episode of the Onco’Zine Brief, Peter Hofland, Ph.D., talks with:
- Eric Vi...
Mark as Played
August 19, 2022 • 45 mins
Glioblastoma is an aggressive type of cancer that can occur in the brain or spinal cord. And while the disease can occur at any age, it tends to occur more often in older people.
According to the American Cancer Society, United States, doctors diagnose between 12,000 and 14,000 patients with glioblastoma in the U.S. each year. There is currently no cure for glioblastoma. The median length of survival after a diagnosis is 15-
18 month...
According to the American Cancer Society, United States, doctors diagnose between 12,000 and 14,000 patients with glioblastoma in the U.S. each year. There is currently no cure for glioblastoma. The median length of survival after a diagnosis is 15-
18 month...
Mark as Played
June 24, 2022 • 46 mins
Your annual doctors- (or wellness-) visit may not be enough to prevent diseases like cancer. Daily health and lifestyle choices are the key to cancer prevention - but what are these choices? What is important?
In "It’s Time you Knew’ - The Power of Your Choices to Prevent Women's Cancer", board certified gynecological oncologist Dr Valene Wright offers simple and straightforward tools to help women listen to their own body – and i...
In "It’s Time you Knew’ - The Power of Your Choices to Prevent Women's Cancer", board certified gynecological oncologist Dr Valene Wright offers simple and straightforward tools to help women listen to their own body – and i...
Mark as Played
May 24, 2022 • 48 mins
After checking your cholesterol, hemoglobin A1C, and glucose level during your annual wellness check, your primary care phycisian says: 'It looks like we haven't done your genome. Why don't we do that?' How would you respond? If you have a genetic mutation that increases your risk for a treatable medical condition, would you want to know? For many people the answer is yes. But typically, such information has not been a part of rout...
Mark as Played
Research out earlier this year confirms what many doctors had feared: Cancer
screenings dropped significantly during the Covid-19 pandemic.
The study, published in the February 2022 edition of Journal of the National
Comprehensive Cancer Network, examined data from the Ontario Cancer Registry in
Canada. The results showed that in March 2020 the week-to-week rate of cancer diagnosis dropped by 34.3%. And this worries doctors, because ov...
screenings dropped significantly during the Covid-19 pandemic.
The study, published in the February 2022 edition of Journal of the National
Comprehensive Cancer Network, examined data from the Ontario Cancer Registry in
Canada. The results showed that in March 2020 the week-to-week rate of cancer diagnosis dropped by 34.3%. And this worries doctors, because ov...
Mark as Played
January 11, 2022 • 49 mins
In the past 30 years, the survival rate for breast cancer has improved by about 40%, one of the highest survival rates of any cancer. The increase in survival is, in part, due to advances in screening technology as well as improvement in cancer treatment and a better understanding of the biology of cancer. All of which have had an impact on survival.
In this episode of The Onco’Zine Brief Peter Hofland, Ph.D. talks with talking with...
In this episode of The Onco’Zine Brief Peter Hofland, Ph.D. talks with talking with...
Mark as Played
December 11, 2021 • 47 mins
Cancer remains the second leading cause of death in the world, and numbers are on the rise. To respond to the growing need for therapeutic solutions, much research is needed. In this episode of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Susan Pandya, MD.
Pandya is Vice President Clinical Development and Global Head of Cancer Metabolism at Servier Pharmaceuticals. She is also a board-certified Hematologist-Oncologist and a ...
Pandya is Vice President Clinical Development and Global Head of Cancer Metabolism at Servier Pharmaceuticals. She is also a board-certified Hematologist-Oncologist and a ...
Mark as Played
November 18, 2021 • 46 mins
In this episode of The Onco’Zine Brief Peter Hofland Ph.D. talks with Ellen J. Kim, MD. Kim is the Medical Director of the Dermatology Clinic at the Perelman Center for Advanced Medicine and Professor of Dermatology at the Hospital of the University of Pennsylvania. She is also the Lead Principal Investigator for the Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study in cutaneous T-cell lymphoma (CTCL). This st...
Mark as Played
November 1, 2021 • 48 mins
In this episode of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Eyal Talor, Ph.D., a clinical immunologist with over 25 years of hands-on management experience in clinical research and drug development. Talor joined CEL-SCI in October 1993 and was promoted to Chief Scientific Officer in October 2009. CEL-SCI is developing a new immunotherapeutic drug for the treatment of cancer, autoimmune diseases, and infectious diseases. ...
Mark as Played
October 21, 2021 • 48 mins
In this episode of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Diane Simeone, MD, the Committee Chair and Principal Investigator and Executive Committee Chair of the PRECEDE Consortium. Simeone is also the Laura and Isaac Perlmutter Professor of Surgery, Department of Surgery at NYU Grossman School of Medicine, Professor, Department of Pathology at NYU Grossman School of Medicine, Director, Pancreatic Cancer Center and Asso...
Mark as Played
September 30, 2021 • 49 mins
In this episode of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Nader Sanai, MD.
Dr. Sanai is the director of the Ivy Brain Tumor Center and the director of neurosurgical oncology at the Barrow Neurological Institute in Phoenix, Arizona. In this episode of the program Hofland asked Sanai about Phase 0 studies – also known as micro-dosing studies – and why they are so important in the development of promising new drugs. They a...
Dr. Sanai is the director of the Ivy Brain Tumor Center and the director of neurosurgical oncology at the Barrow Neurological Institute in Phoenix, Arizona. In this episode of the program Hofland asked Sanai about Phase 0 studies – also known as micro-dosing studies – and why they are so important in the development of promising new drugs. They a...
Mark as Played
June 22, 2021 • 46 mins
In this episode of The Onco’Zine Brief, developed in collaboration with ADC Review | Journal of Antibody-drug Conjugates (at www.ADCReview.com), Peter Hofland, Ph.D. talks with William (Bill) Newell, JD, Chief Executive Officer and a member of the Board of Directors of Sutro Biopharma (www.sutrobio.com)
Sutro is a clinical-stage drug discovery, development, and manufacturing company using precise protein engineering and rational de...
Sutro is a clinical-stage drug discovery, development, and manufacturing company using precise protein engineering and rational de...
Mark as Played
In this edition of The Onco’Zine Brief Peter Hofland, Ph.D., talks with Mondher Mahjoubi, MD, Chief Executive Officer and Chairman of the Executive Board of Innate Pharma, a clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.
Innate Pharma’s broad pipeline of antibodies includes several poten...
Innate Pharma’s broad pipeline of antibodies includes several poten...
Mark as Played
Popular Podcasts
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations.
If you can never get enough true crime... Congratulations, you’ve found your people.
NFL.com's "Around the NFL" crew (Gregg Rosenthal, Dan Hanzus and Marc Sessler) break down the latest football news, with a dash of mirth.
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Listen to 'The Bobby Bones Show' by downloading the daily full replay.